英医生发现应对乳腺癌速效药 2周癌细胞消失

2016-03-13 腾讯科学 腾讯科学

据BBC报道,英国医生发现有两种药物对于乳腺癌治疗有着明显的效果,这意味着某些女性将不再需要进行化疗。这些药物在257位女性患者的身上进行了测试,主要针对的是十分之一女性乳腺癌患者中的一种特定弱点。专家声称这一发现可以说是定制癌症疗法的垫脚石。负责这项实验的医生们并未预料到会达到这样惊人的效果。他们过去一直在研究药物在确诊和手术进行期间如何对癌症产生作用。但是当医生们进行手术时,部分病人体内的癌症

据BBC报道,英国医生发现有两种药物对于乳腺癌治疗有着明显的效果,这意味着某些女性将不再需要进行化疗。这些药物在257位女性患者的身上进行了测试,主要针对的是十分之一女性乳腺癌患者中的一种特定弱点。

专家声称这一发现可以说是定制癌症疗法的垫脚石。负责这项实验的医生们并未预料到会达到这样惊人的效果。他们过去一直在研究药物在确诊和手术进行期间如何对癌症产生作用。但是当医生们进行手术时,部分病人体内的癌症迹象甚至已经消失。

伦敦癌症研究中心的Judith Bliss教授称:“我们对于这些发现感到十分惊奇,因为这项研究呈现的是一种短期疗效。似乎在某些病人体内出现了复杂的反应,这是一种非常令人着迷的治疗效果。”

研究中所使用的两种药物为拉帕替尼和曲妥单抗(也就是我们通常所说的赫赛汀),它们的治疗目标都是HER2,这种蛋白会促使某些女性患者乳腺癌的增长。赫赛汀会作用在癌细胞表面,而拉帕替尼渗透到细胞内部来使HER2蛋白失去功效。

在不到两个周的治疗时间里,11%的癌症患者体内的癌细胞完全消失,17%的患者体内肿瘤缩小到不到5毫米。目前治疗HER2蛋白阳性乳腺癌的手段就是手术,然后进行化疗和赫赛汀治疗。

但是Bliss教授认为这些发现可能意味着部分乳腺癌患者不再需要化疗。然而这仍然需要进行更多的研究,特别是HER2蛋白阳性乳腺癌的复发风险更高。Bliss教授称:“我们首先必须清楚,我们不能够增加其复发的风险。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-23 jetleo

    快进医保

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-23 jetleo

    HER2蛋白阳性乳腺癌的复发风险更高

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-23 jetleo

    意味着部分乳腺癌患者不再需要化疗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-19 1de833cem82(暂无匿称)

    临床实验成功后意义重大

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-16 任然

    真的假的?继续关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-16 numenboy

    大多数人还是用不起的!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-15 yxch36
  8. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习,继续研究

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习,继续研究

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=72974, encodeId=d67ae29747c, content=快进医保, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:39:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72973, encodeId=5a86e29735a, content=HER2蛋白阳性乳腺癌的复发风险更高, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72972, encodeId=4d40e2972be, content=意味着部分乳腺癌患者不再需要化疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Wed Mar 23 16:38:00 CST 2016, time=2016-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71631, encodeId=aa90e163147, content=临床实验成功后意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sat Mar 19 10:04:00 CST 2016, time=2016-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69589, encodeId=d98a69589a6, content=真的假的?继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9a01693879, createdName=任然, createdTime=Wed Mar 16 12:26:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69555, encodeId=8b0369555bf, content=大多数人还是用不起的!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff5294414, createdName=numenboy, createdTime=Wed Mar 16 08:08:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252074, encodeId=6df512520e45f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Mar 15 08:26:00 CST 2016, time=2016-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69063, encodeId=3800690637d, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69062, encodeId=00786906292, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69061, encodeId=2425690615e, content=好好学习,继续研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Mar 14 08:24:00 CST 2016, time=2016-03-14, status=1, ipAttribution=)]
    2016-03-14 忠诚向上

    好好学习,继续研究

    0

相关资讯

早期乳腺癌患者过分担忧转移复发风险会降低生活质量

最近一项研究表明,许多进行了早期乳腺癌治疗的女性都高估了癌细胞向其他器官迁移的可能性,这样的恐惧会降低她们的生活质量。 该研究对超过1000名新诊断为早期乳腺癌(原位导管腺癌或低风险癌)的女性进行了调查,这些女性发生远端复发(癌症转移到身体其他部位导致癌症复发)的风险都非常低。据领导该项研究的密歇根大学医学院教授Sarah Hawley表示超过三分之一的原位导管腺癌患者和超过四分之一的低风险癌患

EBCC2016:欧洲乳腺癌会议亮点速递

3月9日至11日,第10届欧洲乳癌会议(EBCC2016)在荷兰阿姆斯特丹举行,该会议每两年举办一次,是欧洲较有影响力的乳癌临床科研会议。随着会议的进行,小编为您整理了本次会议的亮点,看看哪些研究进展能够对临床实践产生影响。【乳腺外科】乳癌术后乳房即时重建:分两步走还是一次完成?乳癌切除后的最佳的即时乳腺重建手术方式至今仍有争议。基于移植物的乳腺重建手术(Implant-based breast

Science Translational Medicine:研究表明低剂量化疗使肿瘤得到控制

与试图通过大剂量化疗消灭癌症不同的是,研究人员表示,一种使用低剂量药物的实验性方法可能更好地控制肿瘤。 在最新发表于《Science Translational Medicine》期刊的研究中,H. Lee Moffitt 癌症中心和研究所Pedro Enriquez-Navas 及其同事们针对乳腺癌小鼠探索了替代高剂量化疗及其常见

JAMA Oncol:定期低剂量服用阿司匹林真的可降低民众患结直肠癌风险

背景美国预防医学会建议美国成人服用阿司匹林预防结直肠癌和心血管疾病。然而,使用阿司匹林与民众患癌风险和潜在的副作用之间的关系尚不清楚。 目的该研究的目的是探究服用阿司匹林的潜在好处及对特定癌症的预防作用。研究人员通过两项美国大型前瞻性群组研究即护士健康研究(1980-2010)和医务人员随访研究(1986-2012),对135965名医务人员(88084名女性和47881名男性)进行了随访,每2年

JNCI:哪些乳腺癌患者适合辅助二磷酸盐治疗?

近期有研究表明,使用二磷酸盐治疗可降低乳腺癌骨转移风险,改善患者生存率,但仍欠缺一个满意的生物标志物,以便进行更好的治疗。

科学家在中国人群中发现新型的乳腺癌遗传突变

近日,来自香港大学的研究人员通过研究鉴别出了一种新型的遗传突变和高风险的乳腺癌直接相关,该研究或可帮助进行个体的遗传筛查来寻找中国乳腺癌家族史的发病起源。携带BRCA1和BRCA2遗传突变的个体往往是高风险的乳腺癌发病个体,但这些突变通常仅出现在10%至15%的遗传性乳腺癌中,目前还有许多其它许多突变需要被研究阐明。 在3月10日举办的欧洲乳腺癌会议上,研究者Ava Kwong就描述了和中国少数